#USA #Boston #Intrinsic Therapeutics #Barricaid #Back Surgery

Intrinsic Therapeutics Introduces the Barricaid® Narrow Anchor

Boston, March 4, 2026 – Intrinsic Therapeutics, Inc. has officially announced the introduction of the Barricaid® Narrow Anchor. This device represents a significant leap in technology, enhancing an already approved solution for minimizing reherniation risks after back surgery.

The Barricaid Narrow Anchor is designed to be 25% smaller than its predecessor, the Barricaid® Bone-Anchored Annular Closure Device. This size reduction is not merely aesthetic; it aims to improve the surgical experience by minimizing the necessity for extensive bony removals and decreasing nerve root retraction, therefore, accommodating a broader range of high-risk patients.

Addressing Reherniation in Lumbar Discectomy

Reherniation is a prevalent challenge that patients face after lumbar discectomy, often resulting in chronic pain and the need for additional surgeries. Intrinsic Therapeutics has positioned the Barricaid implant as a solution to this issue. It effectively closes disc wall defects, tackling one of the most significant factors contributing to recurrence. The design enhancements on the Narrow Anchor are made to facilitate a more efficient implantation process during surgical procedures.

Greg Lambrecht, the founder of Barricaid, expressed his enthusiasm for the new product, stating, “Barricaid Narrow Anchor shortens the learning curve and eases access for surgeons adopting annular closure. This innovation makes the benefits of Barricaid accessible to more patients at high risk of recurrent disc issues and disabilities following discectomy.”

Enhanced Features of the Narrow Anchor

Significantly, the Barricaid Narrow Anchor reduces the anchor width from 8mm to 6mm, a change that stemmed from direct feedback from surgeons. The potential advantages include:

• - Reduced Retraction: According to spine simulator measurements, the device leads to a 25% to 40% reduction in nerve root retraction during surgery.
• - Improved Visibility: The newly optimized anchor geometry enhances visibility for surgeons, aiding in more precise placement.
• - User-Friendly Design: Impressively, 95% of surgeons reported that the Narrow Anchor was easy to implant.

Despite its smaller size, the Barricaid Narrow Anchor still met the same rigorous mechanical testing standards as the original 8mm version, demonstrating robust resistance to anchor migration and fracture.

Dr. Robert Eastlack, a notable figure in spine surgery, remarked, “In practice, even minor adjustments can lead to substantial improvements. The Narrow Anchor allows for simpler implantation while achieving the same surgical objectives, ultimately streamlining the procedure and helping more patients benefit from annular closure.”

Recent Developments and Future Outlook

The introduction of the Narrow Anchor aligns with a surge of positive developments for Barricaid, notably including the American Medical Association’s new CPT Code Set for 2026, which incorporates a specific code for bone-anchored annular closures starting on January 1, 2026.

About Barricaid
Developed by Intrinsic Therapeutics, Barricaid is a specialized medical device aimed at significantly reducing the need for reoperations in patients with large annular defects following lumbar discectomy, with studies indicating a reduction of up to 81% in reherniation cases. With nearly 13,000 implementations across diverse clinical populations, Barricaid has received extensive validation through various clinical studies, including two randomized controlled trials.

This commitment to innovation reinforces Intrinsic Therapeutics' dedication to improving outcomes for patients facing surgery due to chronic back issues. As the company continues to push boundaries in spinal health technology, the latest Barricaid Narrow Anchor is set to redefine postoperative recovery for countless individuals.